Iptacopan (also known as LNP023) is a medication being studied for treating ANCA-associated vasculitis, which is a condition where blood vessels become inflamed. This medication works by blocking a specific part of the immune system called the complement pathway. It is designed to reduce inflammation and help patients achieve sustained remission of their disease.

Standard of Care (SOC) refers to the currently approved and commonly used treatments for ANCA-associated vasculitis. This typically includes medications that suppress the immune system to reduce inflammation and prevent damage to blood vessels. The standard treatments are being used as a comparison to evaluate how well iptacopan works.

ANCA-Associated Vasculitis – A rare autoimmune condition where the body’s immune system attacks and damages small blood vessels throughout the body. The disease occurs when certain antibodies called ANCA (antineutrophil cytoplasmic antibodies) mistakenly target neutrophils, a type of white blood cell, leading to inflammation of blood vessels. This inflammation can affect multiple organs, including the kidneys, lungs, skin, and nerves. The condition typically develops gradually, with symptoms varying depending on which blood vessels and organs are affected. Common signs include fatigue, fever, weight loss, and various organ-specific symptoms.